MoneyWorks4Me

ANG Lifesciences India informs about outcome of board meeting

22 Nov 2017 Evaluate

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ANG Lifesciences India has informed that Board of Directors of the Company in its Meeting held on November 21, 2017 has considered and approved the Un-audited Financial Results for the Half Year ended September 30, 2017 along with Statement of Assets and Liabilities as at September 30, 2017 and the Limited Review Report of the Auditors thereon.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1805.10
Dr. Reddys Labs. 1202.70
Cipla 1344.90
Lupin 2018.50
Zydus Lifesciences 1137.00
View more..